Capstone Investment Advisors LLC Invests $217,000 in Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT)

Capstone Investment Advisors LLC acquired a new position in shares of Rocket Pharmaceuticals, Inc. (NASDAQ:RCKTFree Report) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 7,257 shares of the biotechnology company’s stock, valued at approximately $217,000.

Several other large investors also recently made changes to their positions in RCKT. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. increased its position in shares of Rocket Pharmaceuticals by 7.9% during the third quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 13,477 shares of the biotechnology company’s stock worth $276,000 after acquiring an additional 981 shares in the last quarter. Jump Financial LLC bought a new stake in shares of Rocket Pharmaceuticals during the third quarter worth $809,000. Barclays PLC increased its position in shares of Rocket Pharmaceuticals by 7.8% during the third quarter. Barclays PLC now owns 154,409 shares of the biotechnology company’s stock worth $3,163,000 after acquiring an additional 11,192 shares in the last quarter. New York State Common Retirement Fund increased its position in shares of Rocket Pharmaceuticals by 6.1% during the third quarter. New York State Common Retirement Fund now owns 24,124 shares of the biotechnology company’s stock worth $494,000 after acquiring an additional 1,389 shares in the last quarter. Finally, Swiss National Bank increased its position in shares of Rocket Pharmaceuticals by 2.4% during the third quarter. Swiss National Bank now owns 123,800 shares of the biotechnology company’s stock worth $2,537,000 after acquiring an additional 2,900 shares in the last quarter. Institutional investors own 98.39% of the company’s stock.

Rocket Pharmaceuticals Stock Performance

NASDAQ RCKT opened at $21.93 on Tuesday. The firm has a 50-day moving average of $23.50 and a 200-day moving average of $26.20. The company has a debt-to-equity ratio of 0.04, a quick ratio of 10.47 and a current ratio of 10.47. Rocket Pharmaceuticals, Inc. has a 52-week low of $14.89 and a 52-week high of $32.53.

Rocket Pharmaceuticals (NASDAQ:RCKTGet Free Report) last posted its earnings results on Monday, May 6th. The biotechnology company reported ($0.66) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.67) by $0.01. During the same quarter last year, the firm posted ($0.73) EPS. On average, research analysts forecast that Rocket Pharmaceuticals, Inc. will post -2.85 earnings per share for the current fiscal year.

Insider Transactions at Rocket Pharmaceuticals

In other news, CEO Gaurav Shah sold 9,790 shares of the firm’s stock in a transaction dated Thursday, May 16th. The shares were sold at an average price of $23.35, for a total transaction of $228,596.50. Following the completion of the sale, the chief executive officer now owns 728,069 shares in the company, valued at approximately $17,000,411.15. The transaction was disclosed in a filing with the SEC, which is accessible through this link. In other Rocket Pharmaceuticals news, insider Mark Andrew White sold 12,532 shares of Rocket Pharmaceuticals stock in a transaction dated Monday, April 8th. The shares were sold at an average price of $24.64, for a total value of $308,788.48. Following the completion of the sale, the insider now owns 75,226 shares in the company, valued at approximately $1,853,568.64. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Gaurav Shah sold 9,790 shares of Rocket Pharmaceuticals stock in a transaction dated Thursday, May 16th. The stock was sold at an average price of $23.35, for a total transaction of $228,596.50. Following the completion of the sale, the chief executive officer now owns 728,069 shares of the company’s stock, valued at approximately $17,000,411.15. The disclosure for this sale can be found here. In the last 90 days, insiders sold 381,772 shares of company stock worth $10,411,590. 31.10% of the stock is owned by insiders.

Analysts Set New Price Targets

RCKT has been the subject of a number of analyst reports. William Blair reaffirmed an “outperform” rating on shares of Rocket Pharmaceuticals in a research report on Monday. UBS Group decreased their target price on shares of Rocket Pharmaceuticals from $56.00 to $54.00 and set a “buy” rating for the company in a research report on Friday, March 1st. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $65.00 target price on shares of Rocket Pharmaceuticals in a research report on Tuesday, February 27th. StockNews.com raised shares of Rocket Pharmaceuticals to a “sell” rating in a research report on Friday, February 9th. Finally, JPMorgan Chase & Co. decreased their target price on shares of Rocket Pharmaceuticals from $55.00 to $50.00 and set an “overweight” rating for the company in a research report on Tuesday, February 27th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and nine have assigned a buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $52.13.

Read Our Latest Stock Analysis on RCKT

About Rocket Pharmaceuticals

(Free Report)

Rocket Pharmaceuticals, Inc, together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction; and pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia.

Further Reading

Institutional Ownership by Quarter for Rocket Pharmaceuticals (NASDAQ:RCKT)

Receive News & Ratings for Rocket Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rocket Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.